- Home
- BKU vs DNLI Comparison
BKU vs DNLI Comparison
Compare BKU & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BKU | DNLI |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2010 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BKU | DNLI |
|---|---|---|
| Price | $46.60 | $18.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | ★ $51.58 | $34.33 |
| AVG Volume (30 Days) | 879.9K | ★ 1.3M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 14.61 | N/A |
| EPS | ★ 3.53 | N/A |
| Revenue | ★ $21,732,000.00 | N/A |
| Revenue This Year | $16.26 | N/A |
| Revenue Next Year | $4.78 | $408.85 |
| P/E Ratio | $13.19 | ★ N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $32.97 | $12.58 |
| 52 Week High | $52.11 | $23.77 |
Technical Indicators
Market Signals| Indicator | BKU | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 39.79 |
| Support Level | $44.10 | $18.42 |
| Resistance Level | $48.22 | $18.70 |
| Average True Range (ATR) | 1.28 | 0.91 |
| MACD | -0.07 | -0.17 |
| Stochastic Oscillator | 55.89 | 6.69 |
Price Performance
Historical ComparisonAbout BKU BankUnited Inc.
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses. The company also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products including commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.